@article{oai:repo.qst.go.jp:00058497,
 author = {M., Bennett Kevin and Jo, Jun-ichiro and Cabral, Horacio and Bakalova-Zheleva, Rumiana and Aoki, Ichio and 城 潤一郎 and バカロバ ルミアナ and 青木 伊知男},
 journal = {Advanced Drug Delivery Reviews},
 month = {Apr},
 note = {The advent of nanoparticleDDSs (drug delivery systems, nano-DDSs) is opening newpathways to understanding physiology and pathophysiology at the nanometer scale. A nano-DDS can be used to deliver higher local concentrations of drugs to a target region andmagnify therapeutic effects.However, interstitial cells or fibrosis in intractable tumors, as occurs in pancreatic or scirrhous stomach cancer, tend to impede nanoparticle delivery. Thus, it is critical to optimize the type and size of nanoparticles to reach the target. High-resolution 3D imaging provides a means of “seeing” the nanoparticle distribution and therapeutic effects.We introduce the concept of “nano-pathophysiological imaging” as a strategy for theranostics. The strategy consists of selecting an appropriate nano-DDS and rapidly evaluating drug effects in vivo to guide the next round of therapy. In this articlewe classify nano-DDSs　by component carrier materials and present an overview of the significance of nano-pathophysiological MRI.},
 pages = {75--94},
 title = {MR imaging techniques for nano-pathophysiology and theranostics},
 volume = {74},
 year = {2014}
}